ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on CKD, today presented full results from the Phase 2 REGEN-007 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback